Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.44 |
| ▸ | HPGDS | O60760 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323850 | 0.90 | HPGDS (0.38) | USP30HPGDSGPR119TP53 | |
| SCHEMBL6329178 | 0.89 | GPR119 (0.40) | HPGDSGPR119MAPT | |
| SCHEMBL6324664 | 0.84 | HPGDS (0.53) | USP30HPGDSGPR119TP53CKS1B | |
| SCHEMBL6330093 | 0.83 | GPR119 (0.43) | HPGDSGPR119TP53LMNA | |
| SCHEMBL6329284 | 0.81 | KDM1A (0.38) | USP30HPGDSGPR119TP53LMNA | |
| SCHEMBL928188 | 0.80 | MEN1 (0.41) | GPR119TP53MAPTLMNA | |
| SCHEMBL6321817 | 0.80 | GPR119 (0.38) | USP30HPGDSGPR119TP53LMNA | |
| SCHEMBL6324539 | 0.79 | USP30 (0.46) | USP30HPGDSGPR119CKS1BSKP1 | |
| SCHEMBL6324400 | 0.79 | CHRNB2 (0.53) | USP30HPGDSGPR119CKS1BSKP1 | |
| SCHEMBL927931 | 0.79 | USP30 (0.58) | USP30HPGDSCKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | USP30 4503/4885HPGDS 3755/4885GPR119 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.